# India Biosimilar Contract Manufacturing Market > India Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.91% - **2024:** $ 289.82 Million - **2025:** $ 344.63 Million - **2035:** $ 1,948 Million - **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) **Report ID:** MRFR/Pharma/50115-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-biosimilar-contract-manufacturing-market-51873 --- ## Market Summary ## **India Biosimilar Contract Manufacturing Market Overview** As per MRFR analysis, the India Biosimilar Contract Manufacturing Market Size was estimated at 260.05 (USD Million) in 2023. The India Biosimilar Contract Manufacturing Market Industry is expected to grow from 309.2(USD Million) in 2024 to 2,300.1 (USD Million) by 2035. The India Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 20.013% during the forecast period (2025 - 2035). ### **Key India Biosimilar Contract Manufacturing Market Trends Highlighted** A number of main market drivers in the India Biosimilar Contract Manufacturing Market are driving significant growth. A primary factor is the growing prevalence of chronic diseases and the corresponding demand for affordable treatment options. To further enhance the market's potential, the Indian government is actively promoting biosimilars through policies that encourage research and development. Regulatory bodies, such as the Central Drugs Standard Control Organization, are simplifying the approval process for biosimilars, thereby facilitating the entry of manufacturers into the market and raising competition. This market offers a plethora of opportunities that should be evaluated. The enormous availability of a skilled workforce and the lower production costs render Indian manufacturers well-positioned to capitalize on these opportunities. Major pharmaceutical companies are transitioning to delegating biosimilar production to contract manufacturers, which is fostering a favorable environment for Indian firms. Furthermore, partnerships and collaborations with global biotechnology companies can allow local actors to improve their technological capabilities and product offerings. There has been a notable trend in India in recent years of increasing investment in biopharmaceutical infrastructure and technology. The nation is experiencing an increase in the number of facilities that are specifically designed for the production and development of biosimilars, most of which adhere to international standards. Additionally, Indian companies are in pursuit of a greater market share, which is reflected in the growing trend of innovation in biotherapeutic development. Such trends suggest that the biosimilar contract manufacturing sector is both robust and evolving, establishing India as a global centre for the production of these essential therapeutics. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **India Biosimilar Contract Manufacturing Market Drivers** ### **Increasing Chronic Disease Prevalence** The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer in India is a significant driver for the India Biosimilar Contract Manufacturing Market. According to the National Health Profile 2021, India has seen a staggering increase in diabetes prevalence, with over 77 million individuals currently affected. With the World Health Organization estimating that by 2030, diabetes could become the seventh leading cause of death globally, the demand for affordable treatment options such as biosimilars is projected to soar.Established organizations like Biocon and Dr. Reddy's Laboratories, which focus heavily on biosimilars, are expected to meet this increasing demand. The government’s push in the Ayushman Bharat initiative aims to provide healthcare services to around 500 million individuals, which further bolsters the need for effective treatment alternatives. As chronic diseases continue to rise in India, the biosimilar contract manufacturing sector is primed for substantial growth. ### **Government Support and Policy Framework** The Government of India has implemented various policies to promote the development and manufacturing of biosimilars. Initiatives such as the Biotechnology Industry Research Assistance Council aim to encourage the growth of biopharmaceutical innovation, which paves the way for the India Biosimilar Contract Manufacturing Market Industry. In addition, the recent introduction of the 'Pharma Vision 2020' policy outlines competency in the biopharmaceutical sector to enhance access to high-quality medicines.This supportive government framework has led to an increase in Research and Development (R&D) activities, allowing domestic firms to compete globally. With the Indian government's aim to increase the biopharmaceutical market size to USD 100 billion by 2025, the encouragement for contract manufacturing in this area is crucial, stimulating future market growth. ### **Rising Demand for Cost-Effective Biosimilars** The escalating healthcare costs in India present a significant driver for the biosimilar contract manufacturing market. With India being home to over 1.3 billion people, the affordability of medications has become critical. The National Pharmaceutical Pricing Authority has put in place price control measures, ensuring that essential drugs remain affordable. Reports suggest that biosimilars can be up to 30% less expensive than their reference biologics, making them an attractive option for healthcare providers and patients alike.Companies like Intas Pharmaceuticals and Mylan are strategically entering the biosimilar market to cater to this rising demand for economically viable treatment options. As the price-sensitive Indian population seeks effective yet affordable treatments, the demand for biosimilars is set to increase, significantly fuelling market growth. ### **Technological Advancements in Biologics Manufacturing** Technological advancements in biologics manufacturing are redefining the capabilities of the India Biosimilar Contract Manufacturing Market Industry. The adoption of cutting-edge techniques such as continuous manufacturing and advanced bioprocessing methods streamlines the production of biosimilars, enhancing yield and reducing costs. Research by the Department of Biotechnology highlights that innovative bioreactor technology and automation can boost productivity by 20-30%.Notable firms like Parexel and Lonza are at the forefront of implementing these advanced technologies in India, significantly impacting operational efficiency. Enhanced manufacturing capabilities will enable Indian companies to meet the growing demand for biosimilars, solidifying their position in the global market and promoting extensive growth in this sector. ## **India Biosimilar Contract Manufacturing Market Segment Insights** ### **Biosimilar Contract Manufacturing Market Product Insights** The India Biosimilar Contract Manufacturing Market has been experiencing significant growth, with the Product segment playing a pivotal role in shaping its dynamics. Particularly noteworthy within this segment are Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, both of which hold essential positions in the production of biosimilars. Recombinant Non-glycosylated Proteins are vital due to their simpler structures, leading to lower production costs and quicker development timelines. This sub-segment dominates the industry by catering to various applications within therapeutics, enhancing drug efficacy, and ensuring patient safety. On the other hand, Recombinant Glycosylated Proteins account for a crucial part of the market because they tend to closely mimic the natural proteins found in human systems. This similarity often results in enhanced therapeutic effects, increased stability, and improved pharmacokinetics, thus driving demand across multiple therapeutic areas, including oncology and autoimmune diseases. The landscape for both these categories is driven by advancements in biotechnology, evolving regulatory frameworks, and a growing need for affordable healthcare solutions in India.The government’s initiatives to promote biotechnology and reduce healthcare costs support the growth trajectory, further bolstering the position of these products within the India Biosimilar Contract Manufacturing Market. With increasing investments in Research and Development, coupled with advancements in technology, the competitive environment for these products is expected to strengthen, paving the way for innovative solutions to emerge. Additionally, as the healthcare sector in India continues to expand, the demand for biosimilars is expected to rise steadily, highlighting the significant opportunities available in both Recombinant Non-glycosylated and Glycosylated Protein spaces. The growth drivers for this market segment include the rising prevalence of chronic diseases, increased healthcare expenditure, and a growing acceptance of biosimilar products among healthcare professionals and patients alike. Despite facing challenges such as stringent regulatory requirements and the need for extensive clinical trials, the overall outlook for the Product segment remains positive, with prospects for continuous evolution and expansion in the coming years. The integration of digital technologies and automation in production processes is further expected to enhance efficiency and reduce operational costs, positioning the India Biosimilar Contract Manufacturing Market as a key player in the global biosimilars landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Biosimilar Contract Manufacturing Market Production Technology Insights** The Production Technology segment of the India Biosimilar Contract Manufacturing Market encompasses critical advancements in the development and manufacturing processes of biosimilars. This segment is categorized into two primary areas Mammalian and Non-Mammalian technologies, each playing a vital role in the efficiency and effectiveness of biosimilar production. Mammalian systems are often preferred for their ability to perform complex post-translational modifications, making them suitable for producing more sophisticated therapeutic proteins.This capability is essential for ensuring that biosimilars mimic the original biologics closely, which is crucial for therapeutic efficacy and regulatory approval. In contrast, Non-Mammalian systems, such as yeast and bacteria, offer advantages in cost efficiency and faster production times, making them significant in meeting the increasing demand for biosimilars. The diversity in production technologies allows India to cater to various therapeutic areas while adapting to global standards. Given the rise in chronic diseases and a growing patient population in India, the significance of these production technologies cannot be overstated, as they align with the strategic goals of enhancing healthcare access and affordability in the region.The India Biosimilar Contract Manufacturing Market is witnessing a shift towards innovation and technological advancements, reflecting the nation's commitment to becoming a global leader in biomanufacturing. ### **Biosimilar Contract Manufacturing Market Application Insights** The Application segment of the India Biosimilar Contract Manufacturing Market highlights a crucial area of growth and expansion in the healthcare sector, focusing on various therapeutic areas such as Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and [Rheumatoid Arthritis](../../../reports/rheumatoid-arthritis-market-1658). With the rising prevalence of cancer and chronic diseases in India, the demand for effective biosimilar solutions is becoming increasingly significant. Oncology is a major focal point due to the growing cancer population, driving innovations in treatment methodologies. Blood Disorders, including conditions like anemia, are also gaining traction, necessitating cost-effective alternatives to branded biologics. In addition, the therapeutic area addressing Growth Hormonal Deficiency showcases the importance of personalized medicine in improving patient outcomes. Chronic and Autoimmune Disorders are increasingly impacting the Indian populace, placing immense pressure on healthcare systems to provide accessible treatment options, thus underscoring the importance of biosimilars. As healthcare strategies evolve, the sub-segment concerning Rheumatoid Arthritis holds a vital role in addressing chronic inflammation and joint disease, providing substantial relief to affected individuals. The diversity within this segment reflects the broader trends affecting the India Biosimilar Contract Manufacturing Market, where increased access, cost-efficiency, and efficacy of treatments represent key growth drivers in the industry. ## **India Biosimilar Contract Manufacturing Market Key Players and Competitive Insights** The India Biosimilar Contract Manufacturing Market has emerged as a critical segment within the pharmaceutical industry, characterized by rapid growth and increased competition. The rising demand for cost-effective alternatives to biological drugs and the increasing focus on precision medicine primarily drive this market. With a plethora of companies vying for market share, the landscape becomes defined by strategic collaborations, technological advancements, and significant investments aimed at enhancing manufacturing capabilities. The competition is further intensified by the regulatory environment that governs the approval and commercialization of biosimilars, necessitating manufacturers to adopt agile and compliant processes. Companies are keenly observing market trends to differentiate their offerings and effectively cater to the diverse needs of healthcare providers and patients.Sun Pharmaceutical Industries has established a prominent foothold in the India Biosimilar Contract Manufacturing Market, leveraging its extensive experience and robust R&D capabilities. The company is recognized for its strong product portfolio, which includes a variety of biosimilar options targeted at chronic diseases such as cancer and autoimmune disorders. Sun Pharmaceutical's significant investment in state-of-the-art manufacturing facilities enables it to maintain high-quality standards while ensuring compliance with stringent regulatory guidelines. The company’s strategic alliances and partnerships further bolster its market presence, fostering innovation and enhancing its competitive edge. Additionally, Sun Pharmaceutical's commitment to cost-effective solutions allows it to cater to a broader patient base, thereby contributing to its growth and stability within this segment. Biocon has emerged as a key player in the India Biosimilar Contract Manufacturing Market, distinguished by its comprehensive range of biopharmaceutical products and services. The company offers biosimilars focused on diabetes, oncology, and autoimmune diseases, gaining a solid reputation for its commitment to quality and efficacy. Biocon has made significant strides in expanding its manufacturing capabilities through modern facilities that meet international standards, positioning itself as an attractive partner for contract manufacturing services. The company has also engaged in strategic collaborations and mergers that enhance its production capacity and market reach, further solidifying its position in the biosimilars sector. Biocon's ongoing efforts in research and development, coupled with its strong market presence, enable it to remain competitive within the growing landscape of biosimilars in India. ### **Key Companies in the India Biosimilar Contract Manufacturing Market Include** ### **India Biosimilar Contract Manufacturing Market Industry Developments** In the India Biosimilar Contract Manufacturing Market, significant recent developments include the ongoing expansion efforts of leading firms such as Sun Pharmaceutical Industries and Biocon. Sun Pharma has been enhancing its production capabilities to meet rising global biosimilar demands. In June 2023, Biocon announced its strategic partnership with Siro Clinpharm, aimed at bolstering its contract research and manufacturing services, reflecting a growth trend in collaborative ventures. Intas Pharmaceuticals continues to invest in Research and Development for biosimilars, pushing for innovative drug solutions amidst increasing competition. The market has also seen notable mergers and acquisitions for instance, Hetero Labs acquired a minority stake in a European biosimilar company in July 2023, strengthening its international presence. Companies like Zydus Cadila and Dr Reddy's Laboratories are diversifying their product portfolios, enhancing their manufacturing capabilities to capture a larger market share. The overall market valuation for these companies shows a positive growth trajectory, influenced by rising demand for affordable biologics in India and globally. The Indian government has also been supportive of biosimilar development, fostering an environment conducive to innovation within the sector over the past 2-3 years. ### **India Biosimilar Contract Manufacturing Market Segmentation Insights** #### **Biosimilar Contract Manufacturing Market Product Outlook** #### **Biosimilar Contract Manufacturing Market Production Technology Outlook** #### **Biosimilar Contract Manufacturing Market Application Outlook** ## Market Drivers ### Regulatory Support and Framework The evolving regulatory landscape in India plays a crucial role in shaping the biosimilar contract-manufacturing market. The Indian government has established a comprehensive regulatory framework that facilitates the approval and commercialization of biosimilars. The introduction of guidelines by the Central Drugs Standard Control Organization (CDSCO) has streamlined the approval process, making it more efficient for manufacturers. As of 2025, the approval timeline for biosimilars has reduced significantly, encouraging more companies to enter the market. This regulatory support not only enhances the confidence of investors but also fosters innovation in biosimilar development. The biosimilar contract-manufacturing market benefits from this environment, as contract manufacturers can leverage regulatory clarity to expedite their operations and meet the increasing demand for biosimilars. ### Increasing Healthcare Expenditure The rising healthcare expenditure in India is a pivotal driver for the biosimilar contract-manufacturing market. As the government and private sectors allocate more funds towards healthcare, the demand for affordable treatment options, including biosimilars, is likely to increase. In 2025, healthcare spending in India is projected to reach approximately $370 billion, reflecting a growth rate of around 12% annually. This financial commitment encourages the development and manufacturing of biosimilars, as they offer cost-effective alternatives to expensive biologics. Consequently, contract manufacturers are positioned to capitalize on this trend by providing tailored solutions that meet the growing needs of pharmaceutical companies. The increasing focus on universal healthcare access further amplifies the demand for biosimilars, thereby driving the growth of the biosimilar contract-manufacturing market. ### Growing Chronic Disease Prevalence The rising prevalence of chronic diseases in India is a significant driver for the biosimilar contract-manufacturing market. With conditions such as diabetes, cancer, and autoimmune disorders becoming increasingly common, the demand for effective treatment options is surging. Reports indicate that by 2025, the number of diabetes patients in India is expected to exceed 100 million, creating a substantial market for biosimilars. These biologics offer therapeutic alternatives that are often more affordable than their reference products. As healthcare providers seek to manage these chronic conditions effectively, the reliance on biosimilars is likely to grow. Consequently, contract manufacturers are positioned to play a vital role in supplying the necessary biosimilars to meet this burgeoning demand, thereby driving the growth of the biosimilar contract-manufacturing market. ### Advancements in Biomanufacturing Technologies Technological advancements in biomanufacturing are transforming the landscape of the biosimilar contract-manufacturing market. Innovations such as single-use bioreactors and continuous manufacturing processes are enhancing production efficiency and reducing costs. These technologies enable manufacturers to produce biosimilars at a larger scale while maintaining quality and compliance with regulatory standards. As of 2025, the adoption of these advanced manufacturing techniques is expected to increase, allowing contract manufacturers to respond swiftly to market demands. This shift not only improves the economic viability of biosimilar production but also supports the rapid development of new biosimilars. The biosimilar contract-manufacturing market stands to benefit significantly from these advancements, as they facilitate the timely delivery of high-quality products to pharmaceutical companies. ### Rising Awareness and Acceptance of Biosimilars The growing awareness and acceptance of biosimilars among healthcare professionals and patients are crucial drivers for the biosimilar contract-manufacturing market. Educational initiatives and outreach programs have been instrumental in informing stakeholders about the safety and efficacy of biosimilars. As of 2025, surveys indicate that approximately 70% of healthcare providers in India are now familiar with biosimilars, leading to increased prescriptions. This shift in perception is vital, as it encourages pharmaceutical companies to invest in biosimilar development and manufacturing. The biosimilar contract-manufacturing market is likely to experience growth as more companies seek to capitalize on this trend, providing the necessary infrastructure and expertise to meet the rising demand for biosimilars. ## Future Outlook The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to grow at 18.91% CAGR from 2025 to 2035, driven by increasing demand for affordable biologics and regulatory support. **New opportunities:** - Establishing strategic partnerships with biotech firms for co-development projects. - Investing in advanced bioprocessing technologies to enhance production efficiency. - Expanding service offerings to include regulatory compliance consulting for biosimilars. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical manufacturing. ## Segment Insights ### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing) In the India biosimilar contract-manufacturing market, the distribution of market share is heavily skewed towards recombinant glycosylated proteins, which currently dominate the market due to their extensive applications in therapeutic areas such as oncology and autoimmune diseases. On the other hand, recombinant non-glycosylated proteins are gaining traction, particularly in niche segments, indicating an increasing diversity within the market. The growth trends for these segments showcase a promising future, particularly for recombinant non-glycosylated proteins, which are recognized as the fastest-growing segment. This growth is attributed to advancements in bioprocessing technologies, improved regulatory frameworks, and the rising demand for innovative biologics. As healthcare providers and patients seek effective treatment solutions, the biosimilar manufacturing capabilities related to these segments are expected to expand significantly. Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging) Recombinant glycosylated proteins are the dominant force in the India biosimilar contract-manufacturing market, recognized for their critical role in meeting the needs of complex biologics. These proteins exhibit higher efficacy and safety profiles, making them preferable for manufacturers and healthcare providers. In contrast, recombinant non-glycosylated proteins represent an emerging segment characterized by their simpler structures and lower production costs. They are increasingly becoming essential for cost-sensitive markets, with their applications broadening within therapeutic areas, including diabetes and other chronic conditions. As manufacturing processes become more sophisticated and cost-efficient, both segments are poised for growth, albeit at differing rates, reflecting their unique market dynamics. ### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing) In the production technology segment of the India biosimilar contract-manufacturing market, Mammalian systems hold the largest share, benefiting from their ability to produce complex proteins and address the demands of high-quality biologics. However, Non-Mammalian systems are increasingly gaining traction, driven by their cost-effectiveness and the rapid development of innovative technologies. These attributes are making them a strong competitor in the landscape of biosimilar production. The growth trends in this segment are characterized by a shift toward biomanufacturing efficiency and sustainability. The demand for biosimilars continues to rise, leading to heightened interest in Non-Mammalian technologies as firms seek to enhance scalability and reduce production costs. Additionally, advancements in cell line development and process optimization are propelling the expansion of both Mammalian and Non-Mammalian approaches in the market. Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging) Mammalian production technology is recognized as the dominant force in the India biosimilar contract-manufacturing market, primarily due to its established infrastructure and proven capability to yield high-quality products suitable for therapeutic applications. It is particularly preferred for producing monoclonal antibodies and other complex biologics. On the other hand, Non-Mammalian technology is emerging as a noteworthy alternative, offering advantages such as faster production cycles and reduced operational costs. It is gaining momentum in applications where rapid turnaround and economic viability are critical. As biosimilar demand increases, the collaboration between established Mammalian processes and innovative Non-Mammalian strategies is anticipated to shape the future of manufacturing efficiencies in this vibrant market. ### By Application: Oncology (Largest) vs. Blood Disorders (Fastest-Growing) In the India biosimilar contract-manufacturing market, the application segment reveals a competitive landscape. Oncology stands out as the largest segment, capturing a significant portion of the market share. Blood Disorders, in contrast, is identified as the fastest-growing segment, attracting increased attention from manufacturers seeking to meet rising healthcare demands. Other applications such as Chronic & Autoimmune Disorders and Rheumatoid Arthritis also contribute to market dynamics but hold smaller proportions compared to these two leading segments. Growth trends indicate a robust demand for biosimilars in the oncology sector, driven by an increasing incidence of cancer and the need for affordable treatment options. Blood Disorders are witnessing rapid growth due to advancements in manufacturing technologies and heightened awareness of treatment accessibility. The ongoing support from healthcare policies further fuels the adoption of biosimilars, enhancing their market presence and paving the way for innovative therapeutic solutions. Oncology (Dominant) vs. Blood Disorders (Emerging) Oncology serves as the dominant application in the India biosimilar contract-manufacturing market, characterized by a substantial variety of biosimilar products aimed at treating various types of cancer. The segment benefits from an established pipeline of biologics, ensuring a steady flow of new therapies into the market. Conversely, Blood Disorders is an emerging segment with rapid growth potential, attracting investment as more companies recognize the necessity of affordable alternatives for therapies like hemophilia. This segment is evolving with innovations aimed at enhancing patient outcomes, supported by a growing understanding of disease treatment in India. The strategic focus on enhancing manufacturing capabilities is vital for both segments to maintain their competitive edge. ## Competitive Benchmarking The biosimilar contract-manufacturing market in India is characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars among healthcare providers. Key players such as Samsung Biologics (KR), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive manufacturing capabilities and technological expertise. Samsung Biologics (KR) focuses on expanding its production capacity and enhancing its technological infrastructure, while Lonza Group (CH) emphasizes partnerships and collaborations to strengthen its market presence. Boehringer Ingelheim (DE) is actively pursuing innovation in bioprocessing technologies, which collectively shapes a competitive environment that is increasingly focused on quality and efficiency.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they set industry standards and drive advancements in manufacturing processes. This competitive structure encourages innovation and efficiency, which are critical for maintaining a competitive edge in the biosimilar sector. In October Samsung Biologics (KR) announced the opening of a new state-of-the-art manufacturing facility in India, aimed at increasing its production capacity for biosimilars. This strategic move is likely to enhance its operational efficiency and reduce lead times, positioning the company favorably in a market that demands rapid delivery of high-quality products. The facility is expected to support both local and global clients, thereby expanding Samsung's footprint in the region. In September Lonza Group (CH) entered into a strategic partnership with a leading Indian biopharmaceutical company to co-develop biosimilars. This collaboration is indicative of Lonza's commitment to leveraging local expertise and resources, which may enhance its ability to navigate regulatory landscapes and meet specific market needs. Such partnerships are crucial for accelerating the development timelines of biosimilars, thereby addressing the growing demand in the Indian market. In August Boehringer Ingelheim (DE) launched a new initiative focused on sustainable biomanufacturing practices in India. This initiative aims to reduce the environmental impact of biosimilar production through innovative technologies and processes. By prioritizing sustainability, Boehringer is not only aligning with The biosimilar contract-manufacturing market increasingly concerned with environmental responsibility. As of November current trends in the biosimilar contract-manufacturing market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their competitive positioning. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation, technological advancements, and the reliability of supply chains, rather than solely on price. This shift suggests a maturation of the market, where quality and efficiency will play pivotal roles in shaping future competition. ## Recent News & Developments In the India Biosimilar Contract Manufacturing Market, significant recent developments include the ongoing expansion efforts of leading firms such as Sun Pharmaceutical Industries and Biocon. Sun Pharma has been enhancing its production capabilities to meet rising global biosimilar demands. In June 2023, Biocon announced its strategic partnership with Siro Clinpharm, aimed at bolstering its contract research and manufacturing services, reflecting a growth trend in collaborative ventures. Intas Pharmaceuticals continues to invest in Research and Development for biosimilars, pushing for innovative drug solutions amidst increasing competition. The market has also seen notable mergers and acquisitions for instance, Hetero Labs acquired a minority stake in a European biosimilar company in July 2023, strengthening its international presence. Companies like Zydus Cadila and Dr Reddy's Laboratories are diversifying their product portfolios, enhancing their manufacturing capabilities to capture a larger market share. The overall market valuation for these companies shows a positive growth trajectory, influenced by rising demand for affordable biologics in India and globally. The Indian government has also been supportive of biosimilar development, fostering an environment conducive to innovation within the sector over the past 2-3 years. ## Report Scope | MARKET SIZE 2024 | 289.82(USD Million) | | --- | --- | | MARKET SIZE 2025 | 344.63(USD Million) | | MARKET SIZE 2035 | 1948.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.91% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) | | Segments Covered | Product, Production Technology, Application | | Key Market Opportunities | Emerging technologies in biomanufacturing enhance efficiency in the biosimilar contract-manufacturing market. | | Key Market Dynamics | Rising demand for cost-effective biosimilars drives competitive contract-manufacturing partnerships in the Indian market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the India biosimilar contract-manufacturing market in 2024?** A: The market valuation was $289.82 Million in 2024. **Q: What is the projected market valuation for the India biosimilar contract-manufacturing market by 2035?** A: The projected valuation for 2035 is $1948.0 Million. **Q: What is the expected CAGR for the India biosimilar contract-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR is 18.91% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the India biosimilar contract-manufacturing market?** A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and others. **Q: What are the two main product segments in the India biosimilar contract-manufacturing market?** A: The main product segments are Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. **Q: What was the market size for Recombinant Glycosylated Proteins in 2024?** A: The market size for Recombinant Glycosylated Proteins was $189.82 Million in 2024. **Q: What production technologies are utilized in the India biosimilar contract-manufacturing market?** A: The production technologies include Mammalian and Non-Mammalian systems. **Q: What was the market size for the Mammalian production technology segment in 2024?** A: The market size for the Mammalian production technology segment was $145.0 Million in 2024. **Q: Which application segment had the highest market size in 2024?** A: The Oncology application segment had the highest market size at $43.0 Million in 2024. **Q: What is the projected growth for the Chronic & Autoimmune Disorders application segment by 2035?** A: The projected market size for Chronic & Autoimmune Disorders is $400.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-biosimilar-contract-manufacturing-market-51873*